title: [Natural history of HCV infection and risk of death in a cohort of patients on long-term hemodialysis].
abstract: BACKGROUND
  HCV infection represents the major cause of chronic liver disease in hemodialysis and renal transplant patients. The clinical course of liver disease in hemodialysis patients is generally asymptomatic. Only few studies describe the natural history of HCV infection in haemodialysis patients, showing an association between HCV infections and poor survival.
  
  
  METHODS
  A prospective cohort study of our haemodialysis population was conducted to define the natural history of HCV infection and its relation to mortality. 77 patients on haemodialysis were enrolled, 24 (31%) of whom were anti-HCV and 53 (69%) anti-HCV-negative.
  
  
  RESULTS
  The HCV-RNA was positive in 18 of the 24 anti-HCV-positive subjects (75%). None of the anti-HCV-negative subjects was HCV-RNA-positive. Eight of the 18 HCV-RNA-positive patients (40%) developed cirrhosis with portal hypertension and ascites within 7 years after the first increase of GPT. Seven of these died, nobody developed hepatocarcinoma (HCC). During 58+/-37-follow-up months mortality rate was higher among anti-HCV-positive patients than among anti-HCV-negative. Besides, the 6 deaths occurred only among anti-HCV-positive and HCV-RNA-positive patients.
  
  
  CONCLUSIONS
  in our haemodialysis patient population the presence of antibodies anti-HCV and HCV-RNA is associated with an increased risk of developing liver cirrhosis and of death, in comparison to anti-HCV-negative patients. Our data show that anti-HCV-positive patients have an accelerated course towards chronic hepatopathy and cirrhosis.
authors.affiliation: U.O. di Nefrologia e Dialisi, Ospedale S. Maria Annunziata, Firenze. pierodattolo@tin.it
authors.forename: P
authors.initials: P
authors.lastname: Dattolo
authors.forename: M
authors.initials: M
authors.lastname: Lombardi
authors.forename: G
authors.initials: G
authors.lastname: Ferro
authors.forename: S
authors.initials: S
authors.lastname: Michelassi
authors.forename: T
authors.initials: T
authors.lastname: Cerrai
authors.forename: F
authors.initials: F
authors.lastname: Pizzarelli
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000032:analysis; D015331:Cohort Studies; D005260:Female; D016174:Hepacivirus / Q000276:immunology / Q000302:isolation & purification*; D006526:Hepatitis C / Q000276:immunology / Q000401:mortality*; D006801:Humans; D007558:Italy; D008103:Liver Cirrhosis / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D006435:Renal Dialysis / Q000706:statistics & numerical data*; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral